NULISA: Ultra-sensitive & Multiplex Immunoassay Platform for Fluid Biomarkers in CNS Disease

Time: 9:30 am
day: Day One


  • New biomarker assay technology, NULISA™ – with ultra-sensitive femtogram level detection with proprietary background suppression technology
  • Unique NULISA CNS Disease Panel detecting nearly 120 critical biomarkers covering diverse neurological diseases
  • Ultra-sensitive NULISA technology holds great promise to enable early detection and monitoring of neurodegenerative diseases to aid in new therapeutic development.